卡瑞利珠单抗联合伊立替康治疗胃癌效果及对血清BARD1、STAT1影响  

Effect of Carrilizumab Combined with Irinotecan on Gastric Cancer and Serum BARD1 and STAT1

作　　者：张慧[1] 黄雯 潘英[1] ZHANG Hui;HUANG Wen;PAN Ying(Department of Gastroenterology,the Fourth Affiliated Hospital of Nanjing Medical University,Nanjing 210000,China;Department of Oncology,the Fourth Affiliated Hospital of Nanjing Medical University,Nanjing 210000,China)

机构地区：[1]南京医科大学第四附属医院消化科,南京210000 [2]南京医科大学第四附属医院肿瘤科,南京210000

出　　处：《转化医学杂志》2023年第3期147-151,共5页Translational Medicine Journal

基　　金：国家自然科学进展项目(81802347)。

摘　　要：目的探讨卡瑞利珠单抗联合伊立替康治疗胃癌的效果及对血清乳腺癌1号基因相关环指蛋白(BARD1)和转录活化蛋白1(STAT1)的影响。方法选取2016年4月—2021年11月收治的胃癌120例,按照治疗方法不同将其分为观察组和对照组2组各60例。观察组给予卡瑞利珠单抗联合伊立替康治疗,对照组给予卡瑞利珠单抗治疗。比较2组治疗后临床效果,治疗后1年生存和复发情况,治疗前后血清肿瘤标志物、免疫功能指标、血清BARD1和STAT1,以及治疗期间毒副作用情况。结果治疗后,观察组总有效率(85.0%,51/60)高于对照组(70.0%,42/60)(P<0.05)。治疗后1年,观察组生存期长于对照组,复发率低于对照组(P<0.05,P<0.01)。治疗后,CD4+、CD4+/CD8+和STAT12组高于治疗前,且观察组高于对照组;血清糖类抗原199、癌胚抗原、CD8+、BARD12组低于治疗前,且观察组低于对照组(P<0.05)。治疗期间,2组毒副作用总发生率比较差异无统计学意义(P>0.05)。结论卡瑞利珠单抗联合伊立替康治疗胃癌患者临床效果较好,可降低血清肿瘤标志物水平,改善免疫功能,还可下调BARD1,上调STAT1,且安全性较好。Objective To investigate the efficacy of Carrilizumab combined with Irinotecan in the treatment of gastric cancer and their effects on serum breast cancer 1 gene-associated ring domain protein(BARD1)and signal transducer and activator of transcription 1(STAT1).Methods In total,120 cases of gastric cancer admitted from April 2016 to November 2021 were selected and divided into observation group(n=60)and control group(n=60)according to different treatment methods.The observation group was treated with Carrilizumab combined with Irinotecan,and the control group was treated with Carrilizumab.The clinical effect,survival and recurrence at 1 year after treatment,serum tumor markers,immune function indexes,serum BARD1 and STAT1 before and after treatment,and toxic and side reactions during treatment were compared between the two groups.Results After treatment,the total effective rate of observation group(85.0%,51/60)was higher than that of control group(70.0%,42/60)(P<0.05).At one year after treatment,the survival time of the observation group was longer than that of the control group,and the recurrence rate was lower than that of the control group(P<0.05,P<0.01).After treatment,CD4+,CD4+/CD8+and STAT1 in the two groups were higher than those before treatment,and higher in the observation group than in the control group.Serum carbohydrate antigen 199,carcinoembryonic antigen,CD8+,and BARD1 in the two groups were lower than those before treatment,and lower in the observation group than in the control group(P<0.05).During treatment,there was no significant difference in the total incidence of toxic and side reactions between the two groups(P>0.05).Conclusion Carrilizumab combined with Irinotikan has good clinical effect in the treatment of gastric cancer patients,which can reduce the level of serum tumor markers,improve immune function,down-regulate BARD1 and up-regulate STAT1,with good safety.

关 键 词：胃肿瘤 卡瑞利珠单抗 伊立替康 糖类抗原199 癌胚抗原 CD4+ 乳腺癌1号基因相关环指蛋白 转录活化蛋白1 

分 类 号：R735.2[医药卫生—肿瘤]